证券代码：002435 证券简称：ST 长康 公告编号：2024-036 长江润发健康产业股份有限公司 2、为完成整改，公司须清收全部被控股股东或者控股股东关联人占用的 资金。 长江润发健康产业股份有限公司（以下简称"公司"）于 2024 年 5 月 10 日收到中国证券监督管理委员会江苏监管局《关于对长江润发健康产业股份有 限公司、长江润发集团有限公司采取责令改正措施的决定》（〔2024〕89 号）（以 下简称"责令改正措施"）。现将具体内容公告如下： 一、责令改正措施的内容 长江润发健康产业股份有限公司、长江润发集团有限公司： 关于收到江苏证监局责令改正措施决定暨风险提示公告 经查，长江润发健康产业股份有限公司（以下简称 ST 长康）控股股东长江 润发集团有限公司（以下简称润发集团）及其关联方前期存在非经营性占用 ST 长康资金的行为。根据 ST 长康公告，截至 2024 年 5 月 6 日，资金占用余额为 348,541.48 万元，占 2023 年末净资产的 93.44%。ST 长康、润发集团的上述行 为违反了《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要 求》（证监会公告[202 ...

证券代码：002435 证券简称：ST 长康 公告编号：2024-035 长江润发健康产业股份有限公司 关于股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 长江润发健康产业股份有限公司（以下简称"公司"）股票（证券名称：ST 长康；证券代码：002435）交易价格连续三个交易日（2024 年 5 月 6 日、5 月 7 日、5 月 8 日）收盘价格跌幅偏离值累计超过 12%，根据《深圳证券交易所交易 规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实情况的说明 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、鉴于公司存在非经营性资金占用、违规担保、公司 2023 年度被出具了 否定已经的内部控制审计报告，根据《深圳证券交易所股票上市规则》第 9.8.1 条第（一）项、第（二）项、第（四）项的规定，公司股票自 2024 年 5 月 6 日起被实施"其他风险警示"的特别处理。截至本公告日披露日，控股股 东资金占用余额为 348,541.48 万元,公司下属子公司为控股股东提供 5 亿元违 ...

深 圳 证 券 交 易 所 关于对长江润发健康产业股份有限公司 2023 年年报的问询函 公司部年报问询函〔2024〕第 85 号 长江润发健康产业股份有限公司董事会： 我部在对你公司 2023 年年度报告（以下简称"年报"）进 行审查的过程中，关注到如下事项： 1、和信会计师事务所（特殊普通合伙）（以下简称"年审 会计师"）对你公司 2023 年度财务报告出具了保留意见，保留 意见涉及关联方非经营性资金占用、违规担保事项，年审会计师 无法判断资金占用部分其他应收账款的准确性、完整性及可收回 性，无法确定是否有必要就违规担保对信用减值损失、预计负债 项目的列报或附注的披露作出调整，以及可能涉及的调整金额或 内容。年审会计师因关联方非经营性资金占用、违规担保事项对 你公司 2023 年度内部控制出具了否定意见。截至 2023 年末，控 股股东长江润发集团有限公司（以下简称"长江润发集团"）及 关联方非经营性资金占用余额合计 164,239.54 万元；截至年报 1 披露日，控股股东及关联方非经营性资金占用余额为 362,541.48 万元。截至 2023 年末及年报披露日，你公司为控股股东提供的 违规担保余额均 ...

证券代码：002435 证券简称：ST长康 公告编号：2024-033 长江润发健康产业股份有限公司 关于控股股东非经营性资金占用进展情况的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 特别提示： 1、截至本公告日披露日，控股股东资金占用余额为 348,541.48 万元。 2、鉴于公司存在非经营性资金占用、违规担保、公司最近一年的内部控制 审计报告被出具否定意见，根据《深圳证券交易所股票上市规则》第 9.8.1 条第 （一）项、第（二）项、第（四）项的规定，公司股票自 2024 年 5 月 6 日起被 实施"其他风险警示"的特别处理。敬请广大投资者注意投资风险、谨慎决策。 一、控股股东及关联方非经营性资金占用情况 长江润发健康产业股份有限公司（以下简称"公司"）在核查中发现存在长 江润发集团有限公司（以下简称"控股股东"或"长江润发集团"）及关联方占 用公司资金的情形,公司聘请的和信会计师事务所（特殊普通合伙）对公司 2023 年度财务报表出具了保留意见，并就资金占用情况出具了《关于对长江润发健康 产业股份有限公司 2023 年度财务报表发表非标准审计意见的 ...

舒知堂先生的独立董事职务辞职生效后，将不再担任公司任何职务。截止本公告日， 舒知堂先生未持有公司股份，不存在应履行而未履行的承诺事项。 舒知堂先生担任公司独立董事期间独立公正、勤勉尽责，在公司业务发展等方面发 挥了重要作用，公司董事会对舒知堂先生在任职期间为公司做出的贡献表示衷心的感谢。 特此公告。 长江润发健康产业股份有限公司 董事会 证券代码：002435 证券简称：ST长康 公告编号：2024-034 长江润发健康产业股份有限公司 关于公司独立董事辞职的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 长江润发健康产业股份有限公司（以下简称"公司"）董事会于近日收到公司独立 董事舒知堂先生的书面辞职报告。因个人原因，舒知堂先生向公司董事会提请辞去第六 届董事会独立董事职务。 舒知堂先生的辞职，将导致公司独立董事人数少于董事会成员的三分之一，根据《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号--主板上市 公司规范运作》等有关规定，舒知堂先生的辞职报告将在公司股东大会选举出新任独立 董事后生效。在此期间，舒知堂先生仍将按照有关 ...

证券代码：002435 证券简称：长江健康 公告编号：2024-032 公司于近日接到长江润发集团的通知，获悉长江润发集团将其所持有公司部 分股份被质押，具体事项公告如下： | 股东 | 是否为控股 | 本次质 | 占其所 | 占公司 | 是否 | 是否 | 质押 | 质押 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股东及其一 | 押数量 | 持股份 | 总股本 | 为限 | 补充 | 起始日 | 到期日 | 质权人 | 用途 | | | 致行动人 | （万股） | 比例 | 比例 | 售股 | 质押 | | | | | | 长江润发 | 是 | 545.00 | 1.63% | 0.44% | 否 | 否 | 2024 年 4 | 办理解除 质押手续 | 张家港市 金港 镇资 | 解决占 用上市 | | 集团 | | | | | | | 月 29 日 | 之日止 | 产经营公 | 公司资 | | | | | | | | | | | 司 | 金事项 | 长江润发健康产业股份有限公司 关 ...

特此公告。 长江润发健康产业股份有限公司 董事会 2024年4月30日 长江润发健康产业股份有限公司 关于举办 2023 年度网上业绩说明会的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 长江润发健康产业股份有限公司（以下简称"公司"）《2023年年度报告 全文及其摘要》已于2024年4月30日在巨潮资讯网(http://www.cninfo.com.cn)披 露。为了便于广大投资者更深入、全面地了解公司情况，公司定于2024年5月20 日（星期一）15:00-17:00采用网络远程的方式举办2023年度网上业绩说明会， 投资者可登录"中国证券网路演中心"（http://roadshow.cnstock.com/）参与本 次年度业绩说明会。 公司出席本次网上业绩说明会人员有：董事长黄忠和先生，总裁卢斌先生， 财务总监张义先生，董事会秘书孙文遥先生，独立董事舒知堂先生。欢迎广大投 资者积极参与。 欢迎广大投资者积极参与！ 证券代码：002435 证券简称：长江健康 公告编号：2024-032 ...

Financial Performance - The company's revenue for Q1 2024 was ¥660,212,418.11, a decrease of 24.42% compared to ¥873,535,602.23 in the same period last year[5] - The net loss attributable to shareholders was ¥10,067,346.72, representing a decline of 116.74% from a profit of ¥60,141,015.34 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0081, down 116.63% from ¥0.0487 in the previous year[5] - The net profit for Q1 2024 was -16,182,681.96 CNY, compared to a net profit of 59,052,807.21 CNY in the same period last year, indicating a significant decline[23] - Operating profit for Q1 2024 was -8,900,429.92 CNY, while the previous year reported an operating profit of 70,853,793.83 CNY, reflecting a substantial decrease[23] - The total comprehensive income for Q1 2024 was -16,174,039.43 CNY, compared to 58,565,124.24 CNY in Q1 2023, showing a drastic decline[23] Cash Flow and Assets - The net cash flow from operating activities was negative at ¥40,621,079.98, a significant drop of 966.40% compared to a positive cash flow of ¥4,688,490.14 in the same period last year[5] - Cash flow from operating activities showed a net outflow of -40,621,079.98 CNY, compared to a net inflow of 4,688,490.14 CNY in Q1 2023[24] - Total cash and cash equivalents at the end of Q1 2024 amounted to 308,664,152.05 CNY, down from 2,401,904,913.35 CNY at the end of Q1 2023[25] - Cash and cash equivalents decreased significantly from ¥2,188,101,935.39 to ¥799,426,653.17, a decline of 63.4%[19] - The company reported cash inflows from investment activities of 2,737,538,473.49 CNY, a significant increase from 631,733,945.51 CNY in the previous year[24] - The net cash flow from financing activities was -105,756,335.19 CNY, compared to a net inflow of 444,881,419.92 CNY in Q1 2023, indicating a shift in financing strategy[25] Expenses and Liabilities - Total operating costs for Q1 2024 were ¥672,489,890.21, down 15.1% from ¥792,274,243.76 in the previous period[21] - Research and development expenses increased by 247.97% to ¥34,994,618.37, reflecting a significant rise in investment in R&D[10] - The company experienced a 59.45% reduction in selling expenses, which totaled ¥74,505,051.84, mainly due to decreased costs in the pharmaceutical sector[10] - Current liabilities totaled ¥4,114,359,330.68, down 1.8% from ¥4,188,793,635.23 in the previous period[19] - Non-current liabilities decreased to ¥699,088,467.32 from ¥759,228,969.01, a reduction of 7.9%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 45,822, with the largest shareholder holding 27.09% of the shares[11] - The company’s shareholder structure indicates significant control by the actual controllers, Yu Qianhe and Yu Xiaqiu, through Changjiang Runfa Group Co., Ltd.[12] - The top ten shareholders include Changjiang Runfa Group Co., Ltd. with 334,831,965 shares and Zhongshan Songde Zhangjiagang Free Trade Zone Pharmaceutical Industry Equity Investment Enterprise with 121,607,997 shares[12] - The company’s major shareholder, Hunan Yongxing Private Fund Management Co., holds 61,500,000 shares through a credit trading guarantee account[13] Government Support and Compliance - The company received government subsidies amounting to ¥13,362,284.73, an increase of 132.24% compared to ¥5,753,740.57 in the previous year[10] - The company has provided a violation guarantee balance of RMB 500.00 million for its controlling shareholder[15] - The company is currently under investigation by the China Securities Regulatory Commission, with no final results available as of the report date[15] - The company has engaged in non-compliant fund transfers totaling RMB 292.35 million through various intermediaries[14] Other Financial Metrics - Total assets at the end of the reporting period were ¥8,566,130,181.61, a decrease of 1.73% from ¥8,716,879,027.28 at the end of the previous year[5] - The company's total equity attributable to shareholders was ¥3,720,122,708.20, slightly down from ¥3,730,181,412.38[20] - The company has maintained a long-term investment of ¥360,000,000.00 in non-current financial assets, unchanged from the previous period[19] - The company reported a significant increase in other receivables, which rose by 107.05% to ¥3,417,280,017.47, primarily due to growth in the machinery sector[10] - The company reported a non-operating fund occupation balance of RMB 1,642.40 million as of December 31, 2023, which includes RMB 1,319.00 million from discounted commercial acceptance bills[14] - As of the report date, the non-operating fund occupation balance from the controlling shareholder and related parties increased to RMB 3,625.41 million[15] - The company’s subsidiary, Changjiang Runfa (Zhangjiagang) Steel Co., Ltd., transferred non-operating funds of RMB 1,930.00 million to the controlling shareholder in early January 2024[15] Strategic Focus - The company’s financial report indicates a focus on expanding its investment in health-related sectors[17] - The company has not reported any new product launches or significant market expansion strategies during this quarter[26]

Financial Performance - The company reported a significant financial challenge, with the auditor issuing a qualified opinion on the financial statements and a negative opinion on internal controls due to issues related to the major shareholder's fund occupation[5]. - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves for the fiscal year 2023[8]. - The company's operating revenue for 2023 was ¥3,238,105,676.32, a decrease of 6.67% compared to ¥3,469,557,831.87 in 2022[27]. - The net profit attributable to shareholders for 2023 was -¥766,728,660.28, representing a significant decline of 1,276.14% from a profit of ¥65,190,392.13 in 2022[27]. - The cash flow from operating activities for 2023 was ¥338,785,649.42, down 35.23% from ¥523,058,080.76 in 2022[27]. - The basic earnings per share for 2023 was -¥0.6203, a decrease of 1,277.04% compared to ¥0.0527 in 2022[27]. - The net profit attributable to shareholders in Q4 2023 was -¥705,614,740.38, a significant decline from a profit of ¥60,141,015.34 in Q1 2023[31]. - The company achieved a total revenue of CNY 3,238.11 million in 2023, a decrease of 6.67% compared to CNY 3,469.56 million in 2022[49]. - The net profit attributable to shareholders was CNY -638.45 million, a significant decline of 1079.36% year-on-year[49]. Business Operations - The company has not experienced any major changes in its main business operations during the reporting period, which continues to focus on pharmaceutical product research, production, and sales, as well as specialized medical services[25]. - The company’s main business remains unchanged, primarily engaging in pharmaceutical manufacturing and related services[24]. - The company operates in three main sectors: pharmaceutical products, maternal and child healthcare services, and elevator guide rail manufacturing[42]. - The company’s pharmaceutical segment is leveraging its established distribution network of over 1,500 distributors to enhance market penetration across 31 provinces and municipalities in China[42]. - The maternal and child healthcare sector, represented by Zhengzhou Shengma Maternity Hospital, has improved its overall medical quality and management, receiving approval for prenatal screening and passing the "secondary A-level" specialty hospital evaluation[44]. - The elevator guide rail manufacturing segment has over 300 product specifications and has established strategic partnerships with major international elevator manufacturers[44]. Innovation and Development - The company emphasized the importance of innovation in the pharmaceutical industry, driven by changing consumer demands and regulatory reforms[38]. - The company has achieved 18 products and 30 specifications passing or deemed equivalent to consistency evaluation in the past three years, with 8 products successfully winning bids in centralized procurement[43]. - The company is benefiting from national policies supporting traditional Chinese medicine, which is expected to bolster the development of its Chinese medicine segment[43]. - The maternal and child healthcare market is anticipated to grow due to increased health awareness and favorable policies, despite a decline in the overall newborn population[40]. - The company is focused on building a modern comprehensive private maternal and child hospital brand, aiming to achieve a top three position in the domestic market[102]. - The company is actively involved in research and development of new technologies to improve its product line and service offerings[132]. Financial Management and Internal Controls - The company has acknowledged the risks associated with its future development strategies and operational goals, advising investors to remain aware of these risks[7]. - The company has not disclosed any specific future financial guidance or performance targets in the report[7]. - The company is committed to improving its internal control systems to enhance operational compliance and risk management[104]. - The company has established a comprehensive internal control system to enhance risk prevention capabilities and ensure compliance with laws and regulations[110]. - The internal control system is deemed adequate for ensuring the preparation of accurate financial statements, although there are significant deficiencies identified in the internal control over financial reporting[163][164]. - The company reported a significant internal control deficiency, resulting in a negative opinion from the auditing firm regarding the effectiveness of financial reporting internal controls as of December 31, 2023[169]. Environmental Compliance - The company is committed to maintaining compliance with environmental laws and standards across its subsidiaries[175]. - The company’s wastewater discharge met the standards set by the Chemical Synthesis Pharmaceutical Industry Water Pollutants Discharge Standards (GB 21904-2008)[175]. - The company achieved a total nitrogen discharge of 0.75 mg/L, which is 30% below the standard limit of 1 mg/L[180]. - The company has effectively controlled total emissions of air pollutants below discharge standards through significant investments in wastewater and air pollution treatment facilities[190]. - The company has received no administrative penalties related to environmental issues during the reporting period[191]. - The company is focusing on expanding its wastewater treatment capacity, with plans to enhance operational efficiency in the coming year[182]. Governance and Shareholder Relations - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, ensuring transparency and participation in decision-making processes[192]. - The company is committed to maintaining the interests of all shareholders, especially minority shareholders[200]. - The board of directors held four meetings during the reporting period to discuss major operational strategies and financial performance[116]. - The company is actively urging related parties to raise funds for repayment to mitigate impacts on operations[200]. - The company has established a long-term mechanism to prevent non-operating fund occupation by related parties, enhancing governance and oversight[123]. Future Outlook - The company aims to achieve a growth rate of over 10% in the upcoming fiscal year, driven by new product launches and market expansion strategies[134]. - The company plans to invest significantly in digital transformation initiatives to improve operational efficiency and customer engagement[134]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its portfolio[134]. - The company plans to enhance internal control measures to prevent non-operating fund occupation by related parties[200].

证券代码：002435 证券简称：长江健康 公告编号：2024-018 长江润发健康产业股份有限公司 关于控股股东及其一致行动人股份质押的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 特别提示： 长江润发健康产业股份有限公司（以下简称"公司"）控股股东长江润发集 团有限公司（以下简称"长江润发集团"）及其一致行动人质押股份数量占其所 持公司股份数量超过 80%，截至目前，公司控股股东及其一致行动人所持股份的 质押风险可控，不存在平仓或被强制平仓风险，请投资者注意相关风险。 公司于近日接到长江润发集团的通知，获悉长江润发集团及其一致行动人将 其所持有公司部分股份被质押，具体事项公告如下： 股东 名称 是否为控股 股东及其一 致行动人 本次质 押数量 （万股） 占其所 持股份 比例 占公司 总股本 比例 是否 为限 售股 是否 补充 质押 质押 起始日 质押 到期日 质权人 质押 用途 长江润发 集团 是 7533.33 22.50% 6.10% 否 否 2024 年 4 月 19 日 办理解除 质押手续 之日止 张家港市国有 资本投资集团 有限公司 自身 资金 ...